Share class: Almirall, S.A.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 213,468,718 76,690,923 ( 35.93 %) 0 35.93 %

Major shareholders: Almirall, S.A.

NameEquities%Valuation
Grupo Corporativo Landon SL
59.88 %
128,614,932 59.88 % 1 931 M €
Norbel Inversiones SL
5.037 %
10,818,595 5.037 % 162 M €
Cobas Asset Management SGIIC SA
1.435 %
3,082,341 1.435 % 46 M €
1.259 %
2,703,324 1.259 % 41 M €
Caixabank Asset Management SGIIC SA
0.7725 %
1,659,153 0.7725 % 25 M €
Bestinver Gestión SA SGIIC
0.4863 %
1,044,450 0.4863 % 16 M €
HSBC Global Asset Management (Switzerland) AG
0.4612 %
990,616 0.4612 % 15 M €
Mutuactivos SA SGIIC
0.3175 %
681,989 0.3175 % 10 M €
Sinergia Advisors 2006 AV SA (Investment Management)
0.2927 %
628,619 0.2927 % 9 M €
Magallanes Value Investors SA SGIIC
0.2841 %
610,207 0.2841 % 9 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Other64.92%
Institutional5.54%
Almirall SA1.26%
Unknown28.28%

Based on 1000 largest holdings

Geographical origin of shareholders

Spain
70.75%
Switzerland
0.49%
France
0.29%
Italy
0.12%
Germany
0.03%
United Kingdom
0.03%
Ireland
0.01%

Based on 1000 largest holdings

Logo Almirall, S.A.
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Employees
2,026